Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Satellos Bioscience Inc MSCLF


Primary Symbol: T.MSCL

Healthcare Biotechnology
Satellos Bioscience Inc. is a Canada-based biotechnology company. The Company is engaged in developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders. The Company is focused on the research in muscle stem cell polarity into a proprietary discovery platform, called MyoReGenX, to identify degenerative muscle diseases where deficits in this process affect muscle regeneration and are amenable to therapeutic intervention. With this platform, the Company is building a pipeline of therapeutics to correct muscle stem cell polarity and promote the body’s innate muscle repair and regeneration process. The Company’s lead program is an oral, small molecule drug candidate in development as a potential disease-modifying treatment for Duchenne muscular dystrophy. It has wholly owned subsidiaries in Australia (Satellos Bioscience Australia Pty Ltd), in Canada (Amphotericin B Technologies, Inc.) and in Delaware, USA (Satellos Bioscience US, Inc.).


TSX:MSCL - Post by User

Satellos Bioscience Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(35)
•••
Post by bmreedon Sep 28, 2024 8:04pm
431 Views
Post# 36245682

Webinar $MSCL CEO Frank Gleeson Oct 3 @ 1PM ET / 10AM PT

Webinar $MSCL CEO Frank Gleeson Oct 3 @ 1PM ET / 10AM PT

Live Webinar - Satellos Bioscience (MSCL) CEO Frank Gleeson and CFO Elizabeth Williams

Thursday, October 3rd at 1PM ET / 10AM PT

Q&A with Radius Research 

Register Here - https://us02web.zoom.us/webinar/register/4017272904267/WN_aeaursgIQSW3Z-aBHM2MZg

 

CEO Frank Gleeson and CFO Elizabeth Williams discuss Satellos' novel treatment technology targeting degenerative muscle diseases. Satellos applies its proprietary discovery platform MyoReGenX™ to identify muscle diseases and disorders where muscle tissue is lost or muscle regeneration is defective. The phase 1 clinical trial of SAT-3247 targeting Duchenne Muscular Dystrophy (DMD) has started.

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities